关键信息
-
基因名
HLA-A*24:02&B2M&p53 Monomer(TYSPALNKMF)
- 应用
-
别名
HLA-A*2402 & B2M & p53 (TYSPALNKMF)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59600.1 (G25-T305)&P61769
-
表达区间
AAA59600.1 (G25-T305)&P61769 (I21-M119)&TYSPALNKMF
-
分子量
39-42 kDa and 10 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
The study of the HLA-A*24:02/B2M/p53 monomer (TYSPALNKMF) recombinant protein is rooted in the significant role of the immune system in cancer immunotherapy. HLA-A*24:02 is a prevalent human leukocyte antigen (HLA) class I molecule that presents tumor-associated peptides, such as those derived from the mutant p53 protein, to cytotoxic T cells, thereby eliciting an immune response. The p53 tumor suppressor gene is frequently mutated in various cancers, leading to the expression of abnormal peptides that can be recognized by the immune system. The B2M (beta-2-microglobulin) is essential for the stability and presentation of the HLA complex on the cell surface. By studying the HLA-A*24:02/B2M/p53 monomer, researchers aim to understand the mechanisms of T cell activation and the specific immune responses generated against p53-derived peptides in cancer patients. This understanding is crucial for developing targeted immunotherapies that can enhance the effectiveness of existing cancer treatments. Furthermore, the recombinant protein serves as a valuable tool for investigating the immunogenicity of p53 peptides, facilitating the design of vaccine candidates that could potentially improve patient outcomes in cancers associated with p53 mutations. Overall, this research holds promise for advancing the field of personalized cancer immunotherapy and improving therapeutic strategies against tumors driven by p53 dysregulation.
